Literature DB >> 20008857

Sorafenib-Related Hand-Foot Skin Reaction Improves, Not Worsens, with Continued Treatment.

Keith T Flaherty1, Marcia S Brose.   

Abstract

Entities:  

Year:  2009        PMID： 20008857     DOI： 10.1158/1078-0432.CCR-09-1190

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  7 in total

1.  Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Authors:  Thomas J Semrad; Courtney Eddings; Chong-Xian Pan; Derick H Lau; David Gandara; Laurel Beckett; Primo N Lara
Journal:  Invest New Drugs       Date:  2011-10-21       Impact factor: 3.850

2.  Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience.

Authors:  Thomas J Semrad; David R Gandara; Primo N Lara
Journal:  Ther Adv Med Oncol       Date:  2011-03       Impact factor: 8.168

3.  Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Authors:  Elizabeth A Kuczynski; Christina R Lee; Shan Man; Eric Chen; Robert S Kerbel
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

Review 4.  Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel.

Authors:  Jade Cury-Martins; Adriana Pessoa Mendes Eris; Cristina Martinez Zugaib Abdalla; Giselle de Barros Silva; Veronica Paula Torel de Moura; Jose Antonio Sanches
Journal:  An Bras Dermatol       Date:  2020-02-15       Impact factor: 1.896

5.  Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.

Authors:  Alexandra Chrisoulidou; Stylianos Mandanas; Efterpi Margaritidou; Lemonia Mathiopoulou; Maria Boudina; Konstantinos Georgopoulos; Kalliopi Pazaitou-Panayiotou
Journal:  Onco Targets Ther       Date:  2015-09-03       Impact factor: 4.147

Review 6.  Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.

Authors:  Fable Zustovich; Giuseppe Lombardi; Davide Pastorelli; Patrizia Farina; Massimo Dal Bianco; Luca De Zorzi; Maurizia Dalla Palma; Ornella Nicoletto; Vittorina Zagonel
Journal:  Open Access J Urol       Date:  2011-05-10

Review 7.  Selective use of sorafenib in the treatment of thyroid cancer.

Authors:  Fabián Pitoia; Fernando Jerkovich
Journal:  Drug Des Devel Ther       Date:  2016-03-11       Impact factor: 4.162
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.